Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Top Cited Papers
Open Access
- 8 May 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 23 (6), 703-713
- https://doi.org/10.1038/nm.4333
Abstract
MSK-IMPACT is a clinical sequencing platform able to detect genomic mutations, copy number alterations and structural variants in a panel of cancer-related genes. This assay is implemented prospectively to inform patient enrollment in genomically matched clinical trials at Memorial Sloan Kettering Cancer Center (MSKCC). Sequencing results of tumor and matched normal tissue from a cohort of >10,000 patients with detailed clinical annotation provide an overview of the genomic landscape of advanced solid cancers and bring new insights into molecularly guided cancer therapy. Tumor molecular profiling is a fundamental component of precision oncology, enabling the identification of genomic alterations in genes and pathways that can be targeted therapeutically. The existence of recurrent targetable alterations across distinct histologically defined tumor types, coupled with an expanding portfolio of molecularly targeted therapies, demands flexible and comprehensive approaches to profile clinically relevant genes across the full spectrum of cancers. We established a large-scale, prospective clinical sequencing initiative using a comprehensive assay, MSK-IMPACT, through which we have compiled tumor and matched normal sequence data from a unique cohort of more than 10,000 patients with advanced cancer and available pathological and clinical annotations. Using these data, we identified clinically relevant somatic mutations, novel noncoding alterations, and mutational signatures that were shared by common and rare tumor types. Patients were enrolled on genomically matched clinical trials at a rate of 11%. To enable discovery of novel biomarkers and deeper investigation into rare alterations and tumor types, all results are publicly accessible.Keywords
This publication has 62 references indexed in Scilit:
- Institutional implementation of clinical tumor profiling on an unselected cancer populationJCI Insight, 2016
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 MutationsThe New England Journal of Medicine, 2015
- Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment ResponseJAMA Oncology, 2015
- Advancing clinical oncology through genome biology and technologyGenome Biology, 2014
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNature Biotechnology, 2013
- Clinical Validation of a Next-Generation Sequencing Screen for Mutational Hotspots in 46 Cancer-Related GenesThe Journal of Molecular Diagnostics, 2013
- Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase InhibitorsThe Journal of Molecular Diagnostics, 2013
- Genomics-Driven Oncology: Framework for an Emerging ParadigmJournal of Clinical Oncology, 2013
- Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot StudyScience Translational Medicine, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationThe New England Journal of Medicine, 2011